Literature DB >> 10899448

Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with charcot-marie-tooth disease 1A duplication.

J Berciano1, A García, J Calleja, O Combarros.   

Abstract

The purpose of the study is to describe the electrophysiologic abnormalities accounting for the appearance and progression of extensor digitorum brevis (EDB) muscle atrophy in Charcot-Marie-Tooth-disease type 1A (CMT-1A) children. Twelve children with CMT-1A duplication were serially evaluated. Initial ages of clinico-electrophysiological exams ranged from 1 month to 4 years (mean: 2 years) and final ages from 6 to 23 years (mean: 13). All subjects had two or more electrophysiological studies of the peroneal nerve. EDB atrophy was observed in two out of 12 (17%) patients by the age of 5, in eight out of ten (80%) examined between 5 and 9 years, and in all eight (100%) patients who had reached the second decade at the end. Nerve conduction maturation was systematically abnormal, but by age of 5 the mean values of nerve conduction parameters of peroneal nerve did not significantly differ from those in older patients. Compound muscle action potential (CMAP) amplitudes of EDB were reduced in 42% of cases initially and 100% upon last exam. Furthermore, a constant finding throughout the study was progressive attenuation of CMAPs, these becoming unobtainable in four cases. EDB muscle atrophy in CMT-1A children is an age-dependent sign which is accounted for by gradual reduction of the distal peroneal nerve CMAP amplitudes.

Entities:  

Mesh:

Year:  2000        PMID: 10899448     DOI: 10.1016/s0960-8966(99)00114-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  18 in total

1.  Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A.

Authors:  Robert Fledrich; Ruth M Stassart; Axel Klink; Lennart M Rasch; Thomas Prukop; Lauren Haag; Dirk Czesnik; Theresa Kungl; Tamer A M Abdelaal; Naureen Keric; Christine Stadelmann; Wolfgang Brück; Klaus-Armin Nave; Michael W Sereda
Journal:  Nat Med       Date:  2014-08-24       Impact factor: 53.440

Review 2.  New insights into the pathophysiology of pes cavus in Charcot-Marie-Tooth disease type 1A duplication.

Authors:  José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2011-05-18       Impact factor: 4.849

3.  Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family.

Authors:  José Berciano; Elena Gallardo; Antonio García; César Ramón; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2010-05-05       Impact factor: 4.849

4.  The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy.

Authors:  Mohtashem Samsam; Weiqian Mi; Carsten Wessig; Jürgen Zielasek; Klaus V Toyka; Michael P Coleman; Rudolf Martini
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

5.  Nerve conduction velocity in CMT1A: what else can we tell?

Authors:  F Manganelli; C Pisciotta; M M Reilly; S Tozza; A Schenone; G M Fabrizi; T Cavallaro; G Vita; L Padua; F Gemignani; M Laurà; R A C Hughes; A Solari; D Pareyson; L Santoro
Journal:  Eur J Neurol       Date:  2016-07-14       Impact factor: 6.089

6.  Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Authors:  Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

Review 7.  Animal models of Charcot-Marie-Tooth disease type 1A.

Authors:  M W Sereda; K-A Nave
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

8.  Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation.

Authors:  Elena Gallardo; Kristl G Claeys; Eva Nelis; Antonio García; Ana Canga; Onofre Combarros; Vincent Timmerman; Peter De Jonghe; José Berciano
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

9.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

10.  MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.

Authors:  Bianca Kohl; Stefan Fischer; Janos Groh; Carsten Wessig; Rudolf Martini
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.